EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Generation and characterization of novel high-affinity fully human antibodies targeting prostate-specific membrane antigen and prostatic acid phosphatase

Claudia Comacchio, Stefanie K Pfister, Domenico Ravazza, Ettore Gilardoni, Tobias Weiss iD, Michael Weller iD, Emanuele Puca, Dario Neri, Roberto De Luca iD

Antibody Therapeutics · 16.10.2025 · 8 (4) · 290-300

DOI: 10.1093/abt/tbaf021 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Antibody Therapeutics, online erschienen am 03.10.2025. Verfasst von Claudia Comacchio und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biology, Philochem AG, Libernstrasse 3, 8112 Otelfingen (ZH), Switzerland. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Philochem AG.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Prostate-specific membrane antigen (PSMA)-targeted therapies have revolutionized the management of patients with prostate cancer. However, not all patients benefit from such agents. Prostatic acid phosphatase (ACP3), a tyrosine phosphatase produced by prostate epithelial cells, has emerged as a promising alternative target for both early and advanced disease.

Methods

Here, we report on the generation and characterization of novel, fully human monoclonal antibodies targeting PSMA and ACP3. Antigen-specific clones were isolated from human antibody phage display libraries and characterized in vitro and in vivo.

Results

Selected clones bound with high specificity to the cognate target and demonstrated excellent tumor-targeting performance in biodistribution studies.

Conclusions

The lead candidates, termed H92A5 (anti-PSMA) and EKA4 (anti-ACP3), could serve as promising scaffolds for the development of next-generation tumor-targeted therapeutics for prostate cancer. Statement of Significance This project developed new fully human antibodies targeting prostate-specific membrane antigen and prostatic acid phosphatase, two key antigens in prostate cancer. These antibodies showed strong and specific tumor binding in animal models. They represent potential tools for improving prostate cancer treatment.

Schlagwörter

Stichwörter der Autor:innen

prostate cancerprostate specific membrane antigenprostatic acid phosphatasetherapeutic antibodiestumor targeting

Autor:innen und Institutionen

  • Department of Biology, Philochem AG, Libernstrasse 3, 8112 Otelfingen (ZH), Switzerland.
  • Department of Neurology, University Hospital & University of Zurich, Rämistrasse 100, 8091 Zurich (ZH), Switzerland.
  • Department of Biology, Philogen Spa, Piazza La Lizza 7, 53100 Siena (SI), Italy.
  • Department of Chemistry and Applied Biosciences, Swiss Federal Institute of Technology (ETH Zürich), Vladimir-Prelog-Weg 1-5/10, 8093 Zurich (ZH), Switzerland.

ORCID-Profile: Tobias Weiss, Michael Weller, Roberto De Luca

Förderung

  • Philochem AG

Zitieren

APA

Comacchio, C., Pfister, S. K., Ravazza, D., Gilardoni, E., Weiss, T., Weller, M., Puca, E., Neri, D., & De Luca, R. (2025). Generation and characterization of novel high-affinity fully human antibodies targeting prostate-specific membrane antigen and prostatic acid phosphatase. Antibody Therapeutics, 8(4), 290-300. https://doi.org/10.1093/abt/tbaf021

Vancouver

Comacchio C, Pfister SK, Ravazza D, Gilardoni E, Weiss T, Weller M, et al. Generation and characterization of novel high-affinity fully human antibodies targeting prostate-specific membrane antigen and prostatic acid phosphatase. Antibody Therapeutics. 2025;8(4):290-300. doi:10.1093/abt/tbaf021

BibTeX
@article{Comacchio2025,
  author = {Comacchio, Claudia and Pfister, Stefanie K and Ravazza, Domenico and Gilardoni, Ettore and Weiss, Tobias and Weller, Michael and Puca, Emanuele and Neri, Dario and De Luca, Roberto},
  title = {Generation and characterization of novel high-affinity fully human antibodies targeting prostate-specific membrane antigen and prostatic acid phosphatase},
  journal = {Antibody Therapeutics},
  year = {2025},
  volume = {8},
  number = {4},
  pages = {290--300},
  doi = {10.1093/abt/tbaf021}
}
Kostenlos starten →